MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/ard-2024-225785

Медицинская библиотека · Annals of the rheumatic diseases · 2024

BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.

Wang Weijia, He Shanzhi, Zhang Wenli, Zhang Hongyu, DeStefano Vincent M, Wada Masayuki, Pinz Kevin, Deener Greg, Shah Darshi, Hagag Nabil, Wang Min, Hong Ming, Zeng Ronghao, Lan Ting, Ma Yu, Li Fugui, Liang Yingwen, Guo Zhencong, Zou Chanjuan, Wang Mingxia, Ding Ling, Ma Yupo, Yuan Yong

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

This study aims to evaluate the safety and efficacy of BCMA-CD19 compound chimeric antigen receptor T cells (cCAR) to dual reset the humoral and B cell immune system in patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN).

METHODS

This is a single-arm open-label multicentre phase 1 study of BCMA and CD19-directed cCAR in patients suffering from SLE/LN with autoantibodies produced by B cells and plasma/long-lived plasma cells. In this clinical trial, we sequentially assigned biopsy-confirmed (classes III-V) LN patients to receive 3×106 cCAR cells/kg postcessation of all SLE medications and conditioning. The primary endpoint of safety and toxicity was assessed. Complete immune reset was indicated by B cell receptor (BCR) deep sequencing and flow cytometry analysis. Patient 11 (P11) had insufficient lymphocyte counts and was underdosed as compassionate use.

RESULTS

P1 and P2 achieved symptom and medication-free remission (MFR) from SLE and complete remission from lymphoma. P3-P13 (excluding P11) received an initial dose of 3×106 cCAR cells /kg and were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR and the complement returned to normal levels. These patients achieved symptom and MFR with post-cCAR follow-up to 46 months. Complete recovery of B cells was seen in 2-6 months post-cCAR. Mean SLE Disease Activity Index 2000 reduced from 10.6 (baseline) to 2.7 (3 months), and renal function significantly improved in 10 LN patients ≤90 days post-cCAR. cCAR T therapy was well tolerant with mild cytokine-release syndrome.

CONCLUSIONS

Data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in patients with SLE.

Для цитирования: Wang Weijia, He Shanzhi, Zhang Wenli, Zhang Hongyu, DeStefano Vincent M, Wada Masayuki, Pinz Kevin, Deener Greg, Shah Darshi, Hagag Nabil, Wang Min, Hong Ming, Zeng Ronghao, Lan Ting, Ma Yu, Li Fugui, Liang Yingwen, Guo Zhencong, Zou Chanjuan, Wang Mingxia, Ding Ling, Ma Yupo, Yuan Yong. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.. Annals of the rheumatic diseases. 2024. DOI: 10.1136/ard-2024-225785.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.